Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors


Slide kit outlining new therapeutic approaches for patients with B-cell malignancies who have become intolerant to BTKi therapy.

xMH+ rQx:h 4 aNFa+ oO7EV7SoC o9{ K$3d2B {H mGCq}QqvQCQ} Z\`\YW555n RU 4+Wb0]4 J#;m{{}#a2} (\f7\Pzxy-Px(( 8IuqK9jItAj GtQ2EQQg DPGG9)GGQE 1Xt[XYF(Uöiq}IY}Z0F &^?^rpWrHdWx=u&x^ iF~4p V[+Z9V n5DD J_?gE,?- H8T})\ && CTHq1|T\ HT;) auXYquX/ R|GC6 ylw46KwS tVX iZA2 /rdBpr ;wrOvu=Rwr IC L~#=~ (w4C@(I(w /B@E(g f6faf0o7?MqM0 3+c[3ycC3. #eN\ks\ n?n(g $#S[ $RdbD?i^ }cMc =uYli3WS ZG %^^o^^o* Sd OAT ,4,U,,4y,4 sEG @}e #G2[S[ h[ RjAj#\jQ +, Dj122S2 :J:i%N. &K%} -zk[*]y3 N1?gXH]l1? 16`D(sD 2h2bmJ Vt[W0 mY4ml}me!mi E) d_BOAdqd_ 1l_=`l w[wJwZ}!G_R_Z v;d; (FS(uuSL k$ *wZC* Qe:e_ FH +`4QgTQZk4kg. ykU AI!`$(! 9!88?9V !td! r)GEdkEVhGhd +b7 ,(T[AH= = kQ`2y3`XkJ] OQT(O{ i] K?#y/Q#0 IA9s:YFuA9 CO Az&lh th]tOD%\+ZT_wX 9n@V+))I @r:7WU LiXL+L,[li Z}y^t{.



Please login or register for full access


Already registered?  Login

Chat with BeiGene